Hoogendoorn M, Feenstra T L, Rutten-van Mölken M P M H
Erasmus MC, Institute for Medical Technology Assessment, Rotterdam.
Ned Tijdschr Geneeskd. 2006 Jun 3;150(22):1243-50.
To determine the health-care utilisation and associated costs for asthma and chronic obstructive pulmonary disease (COPD) in the Netherlands for the year 2000 and to estimate future costs by means of projections.
Descriptive and explorative.
The costs were based on data regarding resource use in 2000 obtained from representative national registries and surveys. The costs were specified by gender and age category and for COPD also by severity. Three projections for the costs of asthma and COPD were made by means of prevalence projections: first assuming constant resource use and constant prices, second assuming asthma- and COPD-specific trends in the costs for hospital care (asthma, -4.7% and COPD, -4.1% per year) and medication (+4.9% per year), and third by adding general trends for the remaining types of care.
Total costs for the year 2000 for asthma (452,000 patients) and COPD (306,000 patients) were estimated to be 141 and 280 million Euros, amounting to 313 en 915 Euros per patient or 9 and 18 Euros per inhabitant, respectively. Projections of total prevalence for the year 2025 varied between 478,000 and 568,000 patients for asthma and between 479,000 and 494,000 patients for COPD. Assuming constant resource use and prices, the costs in 2025 were projected to increase to amounts between 167 and 181 million Euros for asthma and 443 and 495 million Euros for COPD. Projections including the estimated trends in costs for hospital care, medication and the costs for other types of care predicted a sharper increase.
Costs for asthma and COPD together (421 million Euros) amounted to 1.3% of the total Dutch health-care budget in 2000. Almost 70% of these costs were for COPD. Projections for 2025 showed that the costs for COPD will increase more than the costs for asthma.
确定2000年荷兰哮喘和慢性阻塞性肺疾病(COPD)的医疗保健利用情况及相关费用,并通过预测估算未来费用。
描述性和探索性研究。
费用基于2000年从具有代表性的国家登记处和调查中获得的资源使用数据。费用按性别和年龄类别进行分类,对于慢性阻塞性肺病还按严重程度分类。通过患病率预测对哮喘和慢性阻塞性肺病的费用进行了三种预测:第一种假设资源使用和价格不变,第二种假设医院护理费用(哮喘每年-4.7%,慢性阻塞性肺病每年-4.1%)和药物费用(每年+4.9%)有哮喘和慢性阻塞性肺病特定的趋势,第三种通过加上其余护理类型的总体趋势。
2000年哮喘(452,000例患者)和慢性阻塞性肺病(306,000例患者)的总费用估计分别为1.41亿欧元和2.8亿欧元,即每位患者313欧元和915欧元,或每位居民分别为9欧元和18欧元。2025年哮喘的总患病率预测在478,000至568,000例患者之间,慢性阻塞性肺病在479,000至494,000例患者之间。假设资源使用和价格不变,预计2025年哮喘的费用将增至1.67亿至1.81亿欧元之间,慢性阻塞性肺病的费用将增至4.43亿至4.95亿欧元之间。包括医院护理、药物费用和其他护理类型费用的估计趋势在内的预测显示费用增长更为明显。
2000年哮喘和慢性阻塞性肺病的费用总计(4.21亿欧元)占荷兰医疗保健总预算的1.3%。这些费用中近70%用于慢性阻塞性肺病。2025年的预测表明,慢性阻塞性肺病的费用增长将超过哮喘的费用增长。